Low Estrogen Birth Control Pills

Introduction to Low-Dose Formulations

The American Academy of Pediatrics recommends 30-35 μg ethinyl estradiol + levonorgestrel as a first-line option for most women 1, 2
The American Academy of Pediatrics also recommends 30-35 μg ethinyl estradiol + norgestimate, which offers an established safety profile with second-generation progestin benefits 1, 2

Levonorgestrel demonstrates the safest coagulation profile compared to newer progestins, with lower venous thromboembolism risk 1
Second-generation progestins (levonorgestrel, norgestrel) show lower odds ratios for VTE than third and fourth-generation options 1
Third-generation progestins, such as norgestimate and desogestrel, may be considered when acne treatment is a priority, though VTE risk is slightly higher than second-generation options 1

Strict adherence is critical with 20 μg formulations, as seven consecutive days of pill-taking is necessary to reliably prevent ovulation 1
Studies show more follicular activity when 20 μg pills are missed compared to 30 μg formulations 1
Baseline VTE risk increases from 1-5 per 10,000 woman-years to 3-4 per 10,000 woman-years with combined oral contraceptive use, substantially lower than pregnancy-related VTE risk of 10-20 per 10,000 woman-years 2
Formulations containing ≥35 μg ethinyl estradiol show statistically higher odds ratios for VTE than lower doses 1
The American Heart Association recommends lower doses of ethinyl estradiol to minimize stroke risk 1

Estrogen-containing contraceptives are potentially harmful for women at high risk of thromboembolic events, including those with cyanosis, Fontan physiology, mechanical valves, prior thrombotic events, and pulmonary arterial hypertension 4
Women with positive antiphospholipid antibodies should strongly avoid combined estrogen-progestin contraceptives due to increased thromboembolism risk 3, 5
Severe uncontrolled hypertension, ongoing hepatic dysfunction, complicated valvular heart disease, migraines with aura, and thrombophilia are contraindications 1

Women with SLE and moderate/severe disease activity should use progestin-only or IUD contraceptives over combined estrogen-progestin options 3, 5
Women taking tamoxifen should avoid estrogen-containing contraceptives 6

Same-day "quick start" initiation is recommended without requiring gynecologic examination, with only blood pressure measurement needed 2
Use backup contraception for 7 days if starting more than 5 days after menstrual bleeding began 1, 2
The CDC recommends prescribing up to 1 year of combined oral contraceptives at a time 1

Rifampin, rifabutin, certain anticonvulsants, and St. John's wort reduce effectiveness and require backup contraception 2
Broad-spectrum antibiotics, antifungals, and antiparasitics do NOT reduce effectiveness 2
Some antiretroviral agents (ritonavir-boosted protease inhibitors, nevirapine, efavirenz) can reduce hormonal levels 1

Smoking is NOT a contraindication at age <35 years but becomes Category 3-4 at age ≥35 years 2
Do not arbitrarily discontinue combined oral contraceptives at age 40 or 45—the safety profile supports use throughout reproductive years in healthy, non-smoking women 1

Decreased menstrual cramping and blood loss 1, 2
Improvement in acne through anti-androgenic properties 1, 2
Long-term use (>3 years) provides significant protection against endometrial and ovarian cancers 1, 2
Beneficial for anemia, severe dysmenorrhea, endometriosis, abnormal uterine bleeding, and bleeding disorders 1